PLX

PROTALIX生物疗法
AMEX

实时行情|Nasdaq Last Sale

3.620
-0.060
-1.63%
已收盘, 16:38 08/06 EDT
开盘
3.750
昨收
3.680
最高
3.760
最低
3.590
成交量
7.75万
成交额
--
52周最高
4.865
52周最低
1.700
市值
1.17亿
市盈率(TTM)
-5.6020
分时
5日
1月
3月
1年
5年

分析师评级

2位分析师的综合评级

强力推荐

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测

分析师预测PLX价格均价为9.75,最高价位11.00,最低价为8.50。

EPS

PLX 新闻

更多
Protalix BioTherapeutics to Hold Second Quarter 2020 Financial Results and Business Update Conference Call on August 10, 2020
CARMIEL, Israel, Aug. 3, 2020 /PRNewswire/Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary
PR Newswire · 3天前
Protalix reports Non-Binding Term Sheet With SarcoMed To Develop Alidornase Alfa For Treatment Of Pulmonary Sarcoidosis, Related Diseases
Protalix BioTherapeutics, Inc. (NYSE:PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary
Benzinga · 07/23 18:31
Protalix BioTherapeutics Enters into Non-Binding Term Sheet with SarcoMed USA to Develop alidornase alfa for the Treatment of Pulmonary Sarcoidosis and Related Diseases
Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell-based protein expres
PR Newswire · 07/23 18:29
Edited Transcript of PLX.A earnings conference call or presentation 1-Jun-20 12:30pm GMT
Q1 2020 Protalix Biotherapeutics Inc Earnings Call
Thomson Reuters StreetEvents · 07/22 23:28
Have Insiders Been Buying Protalix BioTherapeutics, Inc. (NYSEMKT:PLX) Shares?
Simply Wall St. · 06/18 17:20
Protalix: Investors Should Bear 'Balance' In Mind When Considering The Fabry BLA
Seeking Alpha - Article · 06/16 15:23
Protalix Undervalued Due To Ghost Of Shire, Upside On Fabry Approval Significant
Seeking Alpha - Article · 06/09 12:23
Protalix BioTherapeutics Appoints Yael Hayon, Ph.D. as its New Vice President, Research and Development
Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX) today announced the appointment of Yael Hayon, Ph.D. as the Company's new Vice President, Research and Development, effective July 5, 2020. On June 2, 2020, Yoseph Shaaltiel, Ph.D. retired from hi
PR Newswire · 06/08 21:00

所属板块

生物技术和医学研究
-0.96%
制药与医学研究
-0.46%

热门股票

代码
价格
涨跌幅

PLX 简况

Protalix BioTherapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of recombinant therapeutic proteins based on its ProCellEx protein expression system (ProCellEx). The Company has developed taliglucerase alfa (marketed under the name Uplyso in Brazil and certain other Latin American countries and Elelyso in the rest of the territories) for the treatment of Gaucher disease that has been approved for marketing in the United States, Brazil, Israel and other markets. The Company's product pipeline includes PRX-102 for the treatment of Fabry disease; AIR DNase (PRX-110) for Cystic Fibrosis, and Oral Anti-TNF (OPRX-106) Anti Inflammatory. PRX-102 or alpha-GAL-A is an enzyme replacement therapy product for the treatment of Fabry disease. AIR DNase is a plant cell recombinant human Deoxyribonuclease 1. Oral Anti-TNF represents a mode of administering a recombinant anti-TNF protein.
展开

微牛提供Protalix Biotherapeutics Inc(AMEX-PLX)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的PLX股票新闻,以帮助您做出投资决策。

模拟交易:模拟炒股免费实操交易技能。您可用虚拟资金在真实市场环境中零成本、零风险体验交易PLX股票基本功能。